Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
China 618 Smartphone Sales Drop 13% as Higher Prices Hurt Demand, Huawei Gains Market Share 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
TetherMax Rebranding Highlights Official Exchange Partnerships and Transparent Operations 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
SAN DIEGO, May 07, 2018 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 10, 2018 at 5:30 PM Eastern Time.
The dial-in information is as follows:
Dial-In Number: +1.877.402.3914
Conference ID: 7194327
Prior to the webcast at approximately 4:30 PM Eastern Time on May 10, Cytori will issue its first quarter earnings release which will review Cytori’s first quarter performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
[email protected]
